PharmaTher Partners with KetaMist Inventor to Pursue FDA Approval for Needle-Free Ketamine Platform in Treatment-Resistant Depression
核心洞察
PharmaTher Holdings has entered a collaboration with Dr. Curtis W. Cassidy to advance KetaMist (搜索), a needle-free, patient-controlled ketamine treatment platform, toward FDA approval for treatment-resistant depression (搜索).
KetaMist (搜索) has been used in more than 9,000 patient treatments, generating real-world clinical experience that PharmaTher believes may support an expedited regulatory pathway.
The collaboration targets the growing TRD market, where Johnson & Johnson's Spravato generated approximately $2.0 billion in trailing twelve-month sales through June 2026, with analysts projecting peak annual sales of up to $5 billion.
PharmaTher Holdings Ltd. (搜索) (CSE: PHRM) (OTCQB: PHRRF), a specialty pharmaceutical company focused on personalized medicines for peptides and psychedelics, announced on July 21, 2026, a collaboration with Curtis W. Cassidy, M.D., the inventor and developer of KetaMist (搜索), a needle-free ketamine treatment platform. The partnership aims to pursue U.S. Food and Drug Administration approval for treatment-resistant depression (搜索) (TRD) and other neuropsychiatric and medical conditions where ketamine has demonstrated therapeutic benefit.
KetaMist (搜索) is a proprietary, patient-controlled and needle-free ketamine treatment platform developed by Dr. Cassidy. According to Dr. Cassidy, the platform has been used in more than 9,000 patient treatments, creating what PharmaTher describes as a meaningful body of real-world clinical experience that may support an efficient and potentially expedited FDA development strategy.
The TRD Market Opportunity
Treatment-resistant depression (搜索) represents a significant unmet medical need, affecting millions of patients in the United States who do not respond adequately to standard antidepressant therapies. The current FDA-approved ketamine-based therapy for TRD, Spravato (esketamine nasal spray) from Johnson & Johnson, generated approximately $1.7 billion in worldwide sales in 2025, with trailing twelve-month sales through June 30, 2026 of approximately $2.0 billion. Analysts at Jefferies have reportedly projected that Spravato could generate approximately $3 billion in annual sales by 2027 and up to $5 billion in peak annual sales.
PharmaTher believes KetaMist (搜索) has the potential to compete in this large and growing market by offering a differentiated treatment approach. The platform is designed as a patient-controlled and needle-free delivery system, which may offer several potential advantages, including personalized dosing and administration allowing physicians to tailor treatment to individual patient response, a simplified delivery method potentially improving patient comfort and accessibility, and the use of racemic ketamine, which may provide a differentiated pharmacological profile compared to esketamine.
A Multi-Indication Franchise Vision
Beyond TRD, PharmaTher views KetaMist (搜索) as a franchise platform with the potential to be developed across multiple indications where ketamine has already demonstrated clinical utility. These include depression, anxiety disorders, post-traumatic stress disorder, chronic pain, and other neuropsychiatric and neurological conditions. While many of these uses are currently off-label, the Company believes KetaMist's flexible and personalized delivery approach may support expansion into additional therapeutic areas over time, subject to regulatory approval.
Leveraging Prior FDA Ketamine Experience
PharmaTher previously obtained FDA approval for Ketamine Hydrochloride Injection USP under ANDA #217858, demonstrating the Company's ability to complete the regulatory, manufacturing, analytical and quality requirements necessary to secure an FDA ketamine approval. Although PharmaTher completed the sale of its ANDA in December 2025, the Company retained rights to pursue non-generic ketamine opportunities, including new formulations, delivery technologies and therapeutic indications, along with significant regulatory and product-development experience.
As part of the KetaMist (搜索) collaboration, PharmaTher intends to apply its ketamine regulatory, analytical and chemistry, manufacturing and controls experience to the development program and seek FDA feedback on the most efficient pathway toward approval.
Leadership Perspectives
"KetaMist (搜索) fits our strategy perfectly—a doctor-developed ketamine treatment with over 9,000 patient uses and a path to FDA approval. While we are initially focused on treatment-resistant depression (搜索), we believe KetaMist represents a broader franchise opportunity across multiple indications where ketamine has already shown clinical benefit," said Fabio Chianelli, Chief Executive Officer of PharmaTher. "By combining this real-world experience with our prior FDA-approved ketamine work, we believe we can move faster and more efficiently than traditional drug development and unlock meaningful value across several large markets."
Dr. Curtis W. Cassidy commented: "I developed KetaMist (搜索) to give physicians and patients a more personalized and accessible approach to ketamine treatment. After more than 9,000 patient treatments, we have gained substantial practical experience regarding how patients respond and how treatment may be individualized across a range of conditions. PharmaTher shares that focus on personalized medicine and has the pharmaceutical-development and FDA experience needed to take the next important step toward broader access and potential regulatory approval."
Near-Term Development Priorities
The collaboration activities will include preparing an FDA meeting package to obtain guidance for a potentially accelerated path toward approval. Near-term milestones are expected to include regulatory engagement with the FDA, definition of the clinical and data requirements for a potential New Drug Application submission, and evaluation of how existing real-world data may support the development program.
The collaboration agreement provides PharmaTher with a one-year evaluation period to assess KetaMist (搜索) for potential development and commercial testing. During this period, the parties may negotiate and enter into one or more additional agreements relating to the further development and commercialization of KetaMist, subject to mutually acceptable terms.
KetaMist (搜索) is not currently approved by the FDA, and its existing clinical use is considered off-label. The Company cautions that there can be no assurance that the FDA will accept the proposed regulatory pathway, that the existing treatment information will be suitable for regulatory use, or that KetaMist will receive FDA approval.